Here’s what you need to know:
1. Two-thirds of patients treated with Kanuma for 52 weeks experienced reduced liver fibrosis.
2. Half of patients treated with Kanuma for 52 weeks experienced at least a two-stage reduction in liver fibrosis.
3. Kanuma-treated patients also experienced improvements in alanine aminotransferase, LDL cholesterol and liver fat content.
More articles on gastroenterology and endoscopy:
Takeda Pharmaceutical, New York Academy of Sciences establish $200k research prize: 3 notes
Clinical Genomics’ circulating tumor DNA blood test proves effective for CRC recurrence detection: 3 notes
AGA, NACCME develop 3 regional educational programs about IBD: 3 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
